{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:02:39Z","timestamp":1785445359989,"version":"3.56.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-026-04188-3","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:52:07Z","timestamp":1785444727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimization and formulation of cyclosporine-loaded nanostructured lipid carriers (NLCs) for the management of dry eye syndrome by using centre composite design approaches"],"prefix":"10.1007","volume":"46","author":[{"given":"Harish","family":"Bharwaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagendra","family":"Bhuwane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinendra","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena Devi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"4188_CR1","doi-asserted-by":"publisher","first-page":"8824","DOI":"10.3390\/ijms26188824","volume":"26","author":"M Soyfoo","year":"2025","unstructured":"Soyfoo M, Motulsky E, Sarrand J (2025) Keratoconjunctivitis sicca in Sj\u00f6gren disease: diagnostic challenges and therapeutic advances. Int J Mol Sci 26:8824. https:\/\/doi.org\/10.3390\/ijms26188824","journal-title":"Int J Mol Sci"},{"key":"4188_CR2","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s40123-023-00877-9","volume":"13","author":"A Ballesteros-S\u00e1nchez","year":"2024","unstructured":"Ballesteros-S\u00e1nchez A, S\u00e1nchez-Gonz\u00e1lez J-M, Borrone MA et al (2024) The influence of lid-parallel conjunctival folds and conjunctivochalasis on dry eye symptoms with and without contact lens wear: a review of the literature. Ophthalmol Ther 13:651\u2013670. https:\/\/doi.org\/10.1007\/s40123-023-00877-9","journal-title":"Ophthalmol Ther"},{"key":"4188_CR3","unstructured":"Silva M, Barbosa A, Lima SC, et al Freeze-Dried Softisan\u00ae 649-Based Lipid Nanoparticles for Enhanced Skin Delivery of Cyclosporine A. mdpi.com"},{"key":"4188_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2024-002014","author":"Y Zou","year":"2025","unstructured":"Zou Y, Li D, Gianni V et al (2025) Prevalence of dry eye disease among children: a systematic review and meta-analysis. BMJ Open Ophthalmol. https:\/\/doi.org\/10.1136\/bmjophth-2024-002014","journal-title":"BMJ Open Ophthalmol"},{"key":"4188_CR5","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.3390\/biomedicines11123277","volume":"11","author":"D Borroni","year":"2023","unstructured":"Borroni D, Mazzotta C, Rocha-de-Lossada C et al (2023) Dry eye para-inflammation treatment: evaluation of a novel tear substitute containing hyaluronic acid and low-dose hydrocortisone. Biomedicines 11:3277. https:\/\/doi.org\/10.3390\/biomedicines11123277","journal-title":"Biomedicines"},{"key":"4188_CR6","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.3390\/jcm13061618","volume":"13","author":"A Ballesteros-S\u00e1nchez","year":"2024","unstructured":"Ballesteros-S\u00e1nchez A, S\u00e1nchez-Gonz\u00e1lez J-M, Tedesco GR et al (2024) Evaluating GlicoPro tear substitute derived from Helix aspersa snail mucus in alleviating severe dry eye disease: a first-in-human study on corneal esthesiometry recovery and ocular pain relief. J Clin Med 13:1618. https:\/\/doi.org\/10.3390\/jcm13061618","journal-title":"J Clin Med"},{"key":"4188_CR7","doi-asserted-by":"crossref","unstructured":"Jain S, Mittal A, nanoscience AJ-C, (2011) undefined Enhanced topical delivery of cyclosporin-A using PLGA nanoparticles as carrier. ingentaconnect.com","DOI":"10.2174\/157341311796196835"},{"key":"4188_CR8","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40123-025-01115-0","volume":"14","author":"S Barabino","year":"2025","unstructured":"Barabino S, Aragona P, Baudouin C et al (2025) Parainflammation in the ocular system: considerations on the underlying mechanisms and treatment of dry eye disease. Ophthalmol Ther 14:883\u2013895","journal-title":"Ophthalmol Ther"},{"key":"4188_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40123-023-00868-w","volume":"13","author":"A Ballesteros-S\u00e1nchez","year":"2024","unstructured":"Ballesteros-S\u00e1nchez A, S\u00e1nchez-Gonz\u00e1lez J-M, Tedesco GR et al (2024) Efficacy and safety of quantum molecular resonance electrotherapy in patients with aqueous-deficient, evaporative and mixed-type dry eye: a randomized interventional study. Ophthalmol Ther 13:495\u2013507. https:\/\/doi.org\/10.1007\/s40123-023-00868-w","journal-title":"Ophthalmol Ther"},{"issue":"1\u20132","key":"4188_CR10","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ijpharm.2014.10.067","volume":"477","author":"MF Pinto","year":"2014","unstructured":"Pinto MF, Moura CC, Nunes C, Segundo MA, Lima SAC, Reis S (2014) A new topical formulation for psoriasis: development of methotrexate-loaded nanostructured lipid carriers. Int J Pharm 477(1\u20132):519\u2013526. https:\/\/doi.org\/10.1016\/j.ijpharm.2014.10.067","journal-title":"Int J Pharm"},{"key":"4188_CR11","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.3390\/jcm11051424","volume":"11","author":"C Garc\u00eda-L\u00f3pez","year":"2022","unstructured":"Garc\u00eda-L\u00f3pez C, G\u00f3mez-Huertas C, S\u00e1nchez-Gonz\u00e1lez J-M et al (2022) Opioids and ocular surface pathology: a literature review of new treatments horizons. J Clin Med 11:1424. https:\/\/doi.org\/10.3390\/jcm11051424","journal-title":"J Clin Med"},{"key":"4188_CR12","doi-asserted-by":"publisher","unstructured":"Seyfoddin A, industrial RA-K-D development and, 2013 undefined (2013) Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir. Taylor & Francis 39:508\u2013519. https:\/\/doi.org\/10.3109\/03639045.2012.665460","DOI":"10.3109\/03639045.2012.665460"},{"issue":"1","key":"4188_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3109\/02652040902846883","volume":"27","author":"E Ba\u015faran","year":"2010","unstructured":"Ba\u015faran E, Demirel M, S\u0131rmag\u00fcl B, Yazan Y (2010) Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J Microencapsulation 27(1):37\u201347. https:\/\/doi.org\/10.3109\/02652040902846883","journal-title":"J Microencapsulation"},{"key":"4188_CR14","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/S13346-021-01059-5","volume":"12","author":"S Pandey","year":"2022","unstructured":"Pandey S, Tripathi P, Gupta A, Yadav JS (2022) A comprehensive review on possibilities of treating psoriasis using dermal cyclosporine. Drug Deliv Transl Res 12:1541\u20131555. https:\/\/doi.org\/10.1007\/S13346-021-01059-5","journal-title":"Drug Deliv Transl Res"},{"key":"4188_CR15","unstructured":"Ara\u00fajo J, Garcia M, Mallandrich M, et al Release profile and transscleral permeation of triamcinolone acetonide loaded nanostructured lipid carriers (TA-NLC): in vitro and ex vivo studies. Elsevier"},{"key":"4188_CR16","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S72560","author":"K Wang","year":"2014","unstructured":"Wang K, Qi J, Weng T, Tian Z, Lu Y, Hu K, Wu W (2014) Enhancement of oral bioavailability of cyclosporine A: comparison of various nanoscale drug-delivery systems. Int J Nanomed. https:\/\/doi.org\/10.2147\/IJN.S72560","journal-title":"Int J Nanomed"},{"key":"4188_CR17","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/00007691-199512000-00013","volume":"17","author":"BD Kahan","year":"1995","unstructured":"Kahan BD, Welsh M, Rutzky LP (1995) Challenges in cyclosporine therapy: the role of therapeutic monitoring by area under the curve monitoring. Ther Drug Monit 17:621\u2013624. https:\/\/doi.org\/10.1097\/00007691-199512000-00013","journal-title":"Ther Drug Monit"},{"key":"4188_CR18","doi-asserted-by":"publisher","first-page":"102147","DOI":"10.1016\/j.trim.2024.102147","volume":"88","author":"R Alqadi","year":"2025","unstructured":"Alqadi R, Alqumia A, Alhomoud IS et al (2025) Cyclosporine: immunosuppressive effects, entwined toxicity, and clinical modulations of an organ transplant drug. Transpl Immunol 88:102147. https:\/\/doi.org\/10.1016\/j.trim.2024.102147","journal-title":"Transpl Immunol"},{"key":"4188_CR19","doi-asserted-by":"publisher","unstructured":"Chaudhari P, Ghate VM, Nampoothiri M, Lewis SA (2025) Cyclosporine a eluting nano drug reservoir film for the management of dry eye disease. AAPS PharmSciTech 26:. https:\/\/doi.org\/10.1208\/s12249-025-03104-9","DOI":"10.1208\/s12249-025-03104-9"},{"key":"4188_CR20","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/B978-0-443-29273-6.00015-1","volume-title":"Nanotechnology applications for the diagnosis and therapeutic treatment of fungal diseases","author":"H Kolge","year":"2026","unstructured":"Kolge H, Rudraprasad D, Kumar A (2026) Nanotechnology-based drug delivery systems for ocular fungal infections: advances, challenges, and future directions. Nanotechnology applications for the diagnosis and therapeutic treatment of fungal diseases. Elsevier, pp 437\u2013458"},{"key":"4188_CR21","doi-asserted-by":"publisher","first-page":"6541","DOI":"10.2147\/IJN.S90849","volume":"10","author":"M Guada","year":"2015","unstructured":"Guada M, Sebasti\u00e1n V, Irusta S et al (2015) Lipid nanoparticles for cyclosporine a administration: development, characterization, and in vitro evaluation of their immunosuppression activity. Int J Nanomed 10:6541\u20136553. https:\/\/doi.org\/10.2147\/IJN.S90849","journal-title":"Int J Nanomed"},{"key":"4188_CR22","unstructured":"Guada M, Beloqui A, Kumar M, et al Reformulating cyclosporine A (CsA): more than just a life cycle management strategy. Elsevier"},{"key":"4188_CR23","doi-asserted-by":"publisher","unstructured":"Craig JP, Nichols KK, Akpek EK, et al (2016) Design and development of novel cyclosporine A lipid nanoparticle formulations appropriate for oral delivery. ingentaconnect.com 15:276\u2013283. https:\/\/doi.org\/10.1016\/J.JTOS.2017.05.008","DOI":"10.1016\/J.JTOS.2017.05.008"},{"key":"4188_CR24","doi-asserted-by":"publisher","first-page":"124508","DOI":"10.1016\/j.ijpharm.2024.124508","volume":"662","author":"MA Elmanawy","year":"2024","unstructured":"Elmanawy MA, Boraie N, Bakr BasantA, Makled S (2024) Augmented ocular uptake and anti-inflammatory efficacy of decorated Genistein-loaded NLCs incorporated in in situ gel. Int J Pharm 662:124508. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124508","journal-title":"Int J Pharm"},{"key":"4188_CR25","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/S13346-019-00650-1","volume":"9","author":"D Patel","year":"2019","unstructured":"Patel D, Wairkar S (2019) Recent advances in cyclosporine drug delivery: challenges and opportunities. Drug Deliv Transl Res 9:1067\u20131081. https:\/\/doi.org\/10.1007\/S13346-019-00650-1","journal-title":"Drug Deliv Transl Res"},{"key":"4188_CR26","doi-asserted-by":"crossref","unstructured":"Bao J, Wen Y, Tian L, Jie Y (2025) Decoding allergic conjunctivitis: latest perspectives on etiological drivers and immunopathological mechanisms. Clin. Rev. Allergy Immunol. 68","DOI":"10.1007\/s12016-025-09098-3"},{"key":"4188_CR27","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3390\/pharmaceutics13060905","volume":"13","author":"S Kumari","year":"2021","unstructured":"Kumari S, Dandamudi M, Rani S et al (2021) Dexamethasone-loaded nanostructured lipid carriers for the treatment of dry eye disease. Pharmaceutics 13:905. https:\/\/doi.org\/10.3390\/pharmaceutics13060905","journal-title":"Pharmaceutics"},{"key":"4188_CR28","doi-asserted-by":"publisher","first-page":"125457","DOI":"10.1016\/j.ijpharm.2025.125457","volume":"674","author":"A Mishra","year":"2025","unstructured":"Mishra A, Halder J, Saha I et al (2025) Quercetin loaded biogenic squalene nano-lipid carriers for the treatment of dry eye syndrome. Int J Pharm 674:125457. https:\/\/doi.org\/10.1016\/j.ijpharm.2025.125457","journal-title":"Int J Pharm"},{"key":"4188_CR29","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3390\/pharmaceutics17040478","volume":"17","author":"A Rani","year":"2025","unstructured":"Rani A, Kaur R, Aldahish A et al (2025) Nanostructured lipid carriers (NLC)-based topical formulation of hesperidin for effective treatment of psoriasis. Pharmaceutics 17:478. https:\/\/doi.org\/10.3390\/pharmaceutics17040478","journal-title":"Pharmaceutics"},{"key":"4188_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11080397","author":"PA Makoni","year":"2019","unstructured":"Makoni PA, Kasongo KW, Walker RB (2019) Short term stability testing of efavirenz-loaded solid lipid nanoparticle (SLN) and nanostructured lipid carrier (NLC) dispersions. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics11080397","journal-title":"Pharmaceutics"},{"key":"4188_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2024.11.014","author":"H Bhardwaj","year":"2024","unstructured":"Bhardwaj H, Sahu RK, Jangde RK (2024) Optimization and preparation of doxycycline-loaded chitosan nanoparticles using Box-Behnken design for better diabetic wound healing. J Pharm Sci. https:\/\/doi.org\/10.1016\/j.xphs.2024.11.014","journal-title":"J Pharm Sci"},{"key":"4188_CR32","doi-asserted-by":"publisher","unstructured":"A. Samra T, Elbahwy IA, A. Mowafy H, I. Afouna M (2025) Enhancing ocular drug delivery: development and in vivo evaluation of mucoadhesive nanostructured lipid carriers for terbinafine. Pharm Dev Technol 30:417\u2013429. https:\/\/doi.org\/10.1080\/10837450.2025.2488999","DOI":"10.1080\/10837450.2025.2488999"},{"key":"4188_CR33","doi-asserted-by":"publisher","first-page":"100013","DOI":"10.1016\/j.nxnano.2023.100013","volume":"2","author":"H Bhardwaj","year":"2023","unstructured":"Bhardwaj H, Jangde RK (2023) Current updated review on preparation of polymeric nanoparticles for drug delivery and biomedical applications. Next Nanotechnol 2:100013. https:\/\/doi.org\/10.1016\/j.nxnano.2023.100013","journal-title":"Next Nanotechnol"},{"key":"4188_CR34","doi-asserted-by":"publisher","first-page":"140123","DOI":"10.1016\/j.ijbiomac.2025.140123","volume":"299","author":"D Gu","year":"2025","unstructured":"Gu D, Zhou L, Zhang Y et al (2025) N-acetylcysteine and chitosan conjugate modified dexamethasone nanostructured lipid carriers: enhanced permeability, precorneal retention and lower inflammation for the treatment of dry eye syndrome. Int J Biol Macromol 299:140123. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.140123","journal-title":"Int J Biol Macromol"},{"key":"4188_CR35","unstructured":"Essaghraoui A, Belfkira A, Hamdaoui B, et al Improved dermal delivery of cyclosporine a loaded in solid lipid nanoparticles. mdpi.com"},{"key":"4188_CR36","unstructured":"De Farmacia F (2016) Design and development of novel cyclosporine A lipid nanoparticle formulations appropriate for oral delivery"},{"key":"4188_CR37","doi-asserted-by":"publisher","unstructured":"Patel D, research SW-D delivery and translational, 2019 undefined (2019) Recent advances in cyclosporine drug delivery: challenges and opportunities. Springer 9:1067\u20131081. https:\/\/doi.org\/10.1007\/S13346-019-00650-1","DOI":"10.1007\/S13346-019-00650-1"},{"key":"4188_CR38","doi-asserted-by":"publisher","first-page":"125504","DOI":"10.1016\/j.ijpharm.2025.125504","volume":"675","author":"R Khadke","year":"2025","unstructured":"Khadke R, Shete A, Dashawant A (2025) Design and development of dasatinib nanoemulsions for ocular delivery: in vitro characterization, biocompatibility, and ex vivo ocular irritation study. Int J Pharm 675:125504. https:\/\/doi.org\/10.1016\/j.ijpharm.2025.125504","journal-title":"Int J Pharm"},{"key":"4188_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ph16081151","author":"A Unnisa","year":"2023","unstructured":"Unnisa A, Chettupalli AK, Alazragi RS et al (2023) Nanostructured lipid carriers to enhance the bioavailability and solubility of Ranolazine: statistical optimization and pharmacological evaluations. Pharmaceuticals. https:\/\/doi.org\/10.3390\/ph16081151","journal-title":"Pharmaceuticals"},{"key":"4188_CR40","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2174\/0122117385266639231029192409","volume":"13","author":"V Sabale","year":"2025","unstructured":"Sabale V, Belokar V, Jiwankar M, Sabale P (2025) Nanostructured lipid carrier-loaded in situ gel for ophthalmic drug delivery: preparation and in vitro characterization studies. Pharm Nanotechnol 13:171\u2013183. https:\/\/doi.org\/10.2174\/0122117385266639231029192409","journal-title":"Pharm Nanotechnol"},{"key":"4188_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2025.e41881","author":"MF Tafti","year":"2025","unstructured":"Tafti MF, Fayyaz Z, Aghamollaei H et al (2025) Drug delivery strategies to improve the treatment of corneal disorders. Heliyon. https:\/\/doi.org\/10.1016\/j.heliyon.2025.e41881","journal-title":"Heliyon"},{"key":"4188_CR42","doi-asserted-by":"publisher","first-page":"6034","DOI":"10.1021\/acs.molpharmaceut.4c00554","volume":"21","author":"C Cimino","year":"2024","unstructured":"Cimino C, Zingale E, Bonaccorso A et al (2024) From preformulative design to in vivo tests: a complex path of requisites and studies for nanoparticle ocular application. Part 1: design, characterization, and preliminary in vitro studies. Mol Pharm 21:6034\u20136061. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00554","journal-title":"Mol Pharm"},{"key":"4188_CR43","unstructured":"Shen J, Deng Y, Jin X, et al Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: Improving in vivo ocular distribution. Elsevier"},{"key":"4188_CR44","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2174\/0126673878339109250219072409","volume":"19","author":"AK Singh","year":"2025","unstructured":"Singh AK, Upadhyay PK, Kumar M (2025) Formulation development and permeation studies of vancomycin hydrochloride-loaded nanostructured lipid carrier incorporated thermoresponsive in-situ gel: a Box-Behnken design implemented approach for ocular delivery in endophthalmitis. Recent Adv Drug Deliv Formul 19:235\u2013250. https:\/\/doi.org\/10.2174\/0126673878339109250219072409","journal-title":"Recent Adv Drug Deliv Formul"},{"key":"4188_CR45","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S90849","author":"M Guada","year":"2015","unstructured":"Guada M, Sebasti\u00e1n V, Irusta S, Feijo\u00f3 E, Dios-Vi\u00e9itez MDC, Blanco-Prieto MJ (2015) Lipid nanoparticles for cyclosporine A administration: development, characterization, and in vitro evaluation of their immunosuppression activity. Int J Nanomed. https:\/\/doi.org\/10.2147\/IJN.S90849","journal-title":"Int J Nanomed"},{"key":"4188_CR46","doi-asserted-by":"crossref","unstructured":"Wairkar S, Patel D, and AS-J of drug delivery science, 2022 undefined Nanostructured lipid carrier based dermal gel of cyclosporine for atopic dermatitis-in vitro and in vivo evaluation. Elsevier","DOI":"10.1016\/j.jddst.2022.103365"},{"key":"4188_CR47","doi-asserted-by":"publisher","DOI":"10.1080\/01932691.2025.2526053","author":"SS Chalikwar","year":"2025","unstructured":"Chalikwar SS, Mitkari P, Patil KD et al (2025) Design of experiments-based optimization of rutin-loaded nanostructured lipid carriers: characterization, pharmacokinetics, and stability evaluation. J Dispers Sci Technol. https:\/\/doi.org\/10.1080\/01932691.2025.2526053","journal-title":"J Dispers Sci Technol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04188-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-026-04188-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04188-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:52:10Z","timestamp":1785444730000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-026-04188-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4188"],"URL":"https:\/\/doi.org\/10.1007\/s10792-026-04188-3","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"To the best of the author's understanding, there are no relationships or conflicting financial interests that may have influenced the work reported in this paper.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"319"}}